Ivashkin Vladimir T, Maevskaya Marina V, Shirokova Elena N, Maev Igor V, Samsonov Alexey A, Sas Evgeniy I, Palgova Liudmila K, Starostin Kirill
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia.
Drugs Real World Outcomes. 2021 Sep;8(3):369-382. doi: 10.1007/s40801-021-00250-x. Epub 2021 May 15.
While no "gold-standard" pharmacotherapy for nonalcoholic fatty liver disease (NAFLD) is yet established, essential phospholipids (EPLs) are reported to decrease steatosis and improve laboratory parameters.
This analysis evaluated adherence and satisfaction with EPL treatment as patient-reported outcomes and their relationship with changes in laboratory and ultrasound parameters among Russian patients with NAFLD.
Data were pooled from three observational Russian studies-MANPOWER (2015-2016), LIDER 1 (2012-2013), and LIDER 2 (2013)-in which EPLs were used for at least 12 weeks in the treatment of liver diseases and which measured both subjective and objective endpoints. Only patients who had NAFLD were included in this analysis. The main endpoints were to determine treatment adherence and satisfaction with 12 weeks of EPL therapy, relationship between adherence/satisfaction and changes in the laboratory and ultrasound parameters. A secondary subgroup analysis was performed to identify patients with NAFLD who responded better (or worse) to 24 weeks of adjunctive EPL treatment.
Overall, 3384 patients were included. A total of 82.2% of patients were adherent to 12 weeks of EPL treatment; high/very high satisfaction was reported by 15.3%/65.9% of clinicians and 15.9%/64.4% of patients. There was positive correlation between patients' adherence and satisfaction and significant improvement in laboratory (transaminases, lipid profile; p < 0.001) and ultrasound (steatosis, p < 0.001) parameters, and improvement in symptoms (p < 0.001) after 24 weeks of EPL. Male patients, patients with unhealthy lifestyles, and those with more comorbidities showed a better response in laboratory and ultrasound parameters.
Patients with NAFLD treated with adjunctive EPL therapy in real-world clinical practice in Russia showed good treatment adherence and treatment satisfaction. Improvements in laboratory and ultrasound parameters, as well as dynamics of patient symptoms, were positively correlated with adherence and satisfaction.
虽然尚未确立非酒精性脂肪性肝病(NAFLD)的“金标准”药物治疗方法,但据报道,必需磷脂(EPLs)可减少脂肪变性并改善实验室检查指标。
本分析评估了俄罗斯NAFLD患者对EPL治疗的依从性和满意度(作为患者报告的结局),以及它们与实验室检查和超声检查指标变化之间的关系。
汇总了三项俄罗斯观察性研究——MANPOWER(2015 - 2016年)、LIDER 1(2012 - 2013年)和LIDER 2(2013年)的数据,这些研究中EPLs用于治疗肝病至少12周,且对主观和客观终点均进行了测量。本分析仅纳入了患有NAFLD的患者。主要终点是确定对12周EPL治疗的依从性和满意度、依从性/满意度与实验室检查和超声检查指标变化之间的关系。进行了一项次要亚组分析,以确定对24周辅助EPL治疗反应较好(或较差)的NAFLD患者。
总体而言,共纳入3384例患者。82.2%的患者坚持了12周的EPL治疗;临床医生和患者报告的高/非常高满意度分别为15.3%/65.9%和15.9%/64.4%。患者的依从性和满意度之间呈正相关,并且在接受24周EPL治疗后,实验室检查指标(转氨酶、血脂谱;p < 0.001)和超声检查指标(脂肪变性,p < 0.001)有显著改善,症状也有所改善(p < 0.001)。男性患者、生活方式不健康的患者以及合并症较多的患者在实验室检查和超声检查指标方面反应更好。
在俄罗斯现实世界临床实践中接受辅助EPL治疗的NAFLD患者显示出良好的治疗依从性和治疗满意度。实验室检查和超声检查指标的改善以及患者症状的动态变化与依从性和满意度呈正相关。